Skip to content
Head to head

CRISPR Therapeutics vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: CRSP · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

CRSP -29.3%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
CRSPVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price39.10515.02
Change today+0.44%-1.08%
1-year return-20.7%+22.0%
Market cap$3.79B$130.58B
52-week range38.15 – 63.45412.27 – 568.67
Valuation
P/E (TTM)-8.2733.14
P/E percentile, own 5-yr range53rd99th
P/B2.306.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-6.4715.32
Net profit (TTM)$-627.60M$3.88B
Revenue (TTM)$23.32M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)--+11.8%
Gross margin-676.9%85.5%
Operating margin-2221.7%33.1%
Net margin-1955.7%30.7%
Free cash flow (TTM)$-378.36M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership81.1%96.8%
Insider activity (12mo)34 buy / 13 sell28 buy / 22 sell
Short interest (% of float)17.8%1.9%
Analyst consensus67% buy / 33% hold (12)95% buy / 5% hold (21)
Analyst price target$74 (+90%)$624 (+21%)
StockVane view
StockVane Quant RatingD (18)C (68)
Company
Employees3936,400
Founded20131989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.